Indication :
- The treatment of multiple myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy
- The treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.
Compositions :
Each vial contain Bortezomib 1 mg and Bortezomib 3.5 mg
Storage Condition :
When reconstituted as directed, Bortezomib may be stored at 25°C. Unopened vials may be stored at below 30°C.
Shelf Life :
24 months
